当前位置: 首页 >> 检索结果
共有 16281 条符合本次的查询结果, 用时 4.1535338 秒

121. Implementation challenges of personalised phage therapy.

作者: Sarah Djebara.;Rob Lavigne.;Jean-Paul Pirnay.
来源: Lancet. 2025年405卷10493期1901-1903页

122. Safety of low-intensity monitoring after thrombolysis in acute ischaemic stroke.

作者: Susan Ashcraft.
来源: Lancet. 2025年405卷10493期1884-1885页

123. The need to strengthen the US Food and Drug Administration: US cuts threaten health care at home and abroad.

作者: Jayasree K Iyer.
来源: Lancet. 2025年405卷10496期2188-2191页

124. Zackie Achmat: irrepressible health activist.

作者: Sarah Boseley.
来源: Lancet. 2025年

126. Retraction-Taiwan's national health care on the brink of systemic collapse.

作者: Jing-Xing Li.;Shu-Bai Hsu.
来源: Lancet. 2025年405卷10494期2036页

127. Transcatheter aortic valve implantation: lessons from the ACURATE IDE trial.

作者: Stephan Windecker.;Thomas Pilgrim.
来源: Lancet. 2025年405卷10494期2026-2028页

128. Jacifusen for FUS-ALS: molecular effects and clinical outcomes in a case series.

作者: Naoki Suzuki.;Ayumi Nishiyama.;Satoru Ebihara.;Masashi Aoki.
来源: Lancet. 2025年405卷10494期2028-2030页

129. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.

作者: Neil A Shneider.;Matthew B Harms.;Vlad A Korobeynikov.;Olivia M Rifai.;Benjamin N Hoover.;Elizabeth A Harrington.;Sonya Aziz-Zaman.;Jessica Singleton.;Arish Jamil.;Vikram R Madan.;Ikjae Lee.;Jinsy A Andrews.;Richard M Smiley.;Mahabub M Alam.;Lauren E Black.;Minwook Shin.;Jonathan K Watts.;David Walk.;Daniel Newman.;Robert M Pascuzzi.;Markus Weber.;Christoph Neuwirth.;Sandrine Da Cruz.;Armand Soriano.;Roger Lane.;Scott Henry.;Joel Mathews.;Paymaan Jafar-Nejad.;Dan Norris.;Frank Rigo.;Robert H Brown.;Stephan Miller.;Rebecca Crean.;C Frank Bennett.
来源: Lancet. 2025年405卷10494期2075-2086页
Pathogenic variants of fused in sarcoma (FUS) cause amyotrophic lateral sclerosis (FUS-ALS), with evidence of gain of function. Jacifusen is an antisense oligonucleotide targeting FUS pre-mRNA, previously shown to delay neurodegeneration in a mouse model and potentially slow functional decline in a first-in-human study. Here, we sought to further evaluate use of jacifusen as a treatment for FUS-ALS.

130. The weaponisation of water.

作者: Rebecca Sers.
来源: Lancet. 2025年

131. Emily Mendenhall: applying anthropological thinking to medicine.

作者: Aarathi Prasad.
来源: Lancet. 2025年

132. Deterioration of health outcomes in Gaza: 19 months of protracted conflict.

作者: Laura Paris.;Ghada Al-Jadba.;Wafaa Zeidan.;Paul Spiegel.;Zoheir Elkhatib.;Rami Habash.;Sanaa Al Najjar.;Haya Khammash.;Shatha Albeik.;Tamer Shaer.;Mohannad Ramadan.;Seita Akihiro.
来源: Lancet. 2025年405卷10494期2041-2044页

133. Health and faith partnerships to strengthen trust: the Georgetown-Lancet Commission on Faith, Trust, and Health.

作者: Deus Bazira.;Kezevino Aram.;David Beasley.;Oliver Johnson.;Jack Leslie.;Katherine Marshall.;John Monahan.;Amna Qayyum.;Olivia Wilkinson.
来源: Lancet. 2025年

134. Trachoma.

作者: Esmael Habtamu.;Emma M Harding-Esch.;Katie Greenland.;Teyil Wamyil-Mshelia.;Sandra L Talero.;Sailesh Kumar Mishra.;Thomas M Lietman.;Anthony W Solomon.;Matthew J Burton.
来源: Lancet. 2025年405卷10492期1865-1878页
Trachoma, the leading infectious cause of blindness worldwide, is one of several neglected tropical diseases targeted by WHO for elimination by 2030. The disease starts in childhood with repeated episodes of conjunctival Chlamydia trachomatis infection. This infection is associated with recurrent conjunctivitis (active trachoma), which, if left untreated, leads to cicatricial trachoma characterised by scarring of the conjunctiva, and potentially in-turned eyelashes (trachomatous trichiasis) in later life. Trachoma mainly affects the poorest and most rural communities; these populations typically have limited access to water and hygiene facilities. Blinding complications are most common in women who, in many cultures, act as caregivers from a young age for infected children. To eliminate trachoma as a public health problem, programmes implement a package of interventions known as SAFE; namely, surgery to treat trachomatous trichiasis, antibiotic mass drug administration to treat infection, facial cleanliness, and environmental improvement to limit transmission. The SAFE strategy has brought considerable success in the last two decades. As of December, 2024, 21 countries have eliminated the disease, and several others are on track to eliminate it soon. However, persistent and recrudescent active trachoma in some populations might challenge the success of the 2030 global elimination target. In such settings, novel, or more intensive, approaches must be promptly developed, tested, and scaled up to accelerate elimination.

136. Decentralising clinical trial access requires a culture of health equity.

作者: Sabe Sabesan.;Craig Underhill.;Ramya Thota.;Stephen Sundquist.;Tolulope Adewole.
来源: Lancet. 2025年405卷10492期1816页

137. Logistics of the malaria vaccine roll-out in Nigeria.

作者: Ahmad Olawale Atere.;Fatihi Bamigbola Mustapha.;Mubarak Jolayemi Mustapha.
来源: Lancet. 2025年405卷10492期1815页

138. Gaza has been failed by silence and impunity.

作者: The Lancet.
来源: Lancet. 2025年405卷10492期1791页

139. Accelerating progress on essential medicines: a new Lancet Commission.

作者: Veronika J Wirtz.;Hans V Hogerzeil.;Andrew L Gray.
来源: Lancet. 2025年

140. Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.

作者: Craig S Anderson.;Debbie Summers.;Menglu Ouyang.;Yi Sui.;Brenda Johnson.;Laurent Billot.;Alejandra Malavera.;Roland Faigle.;Paula Muñoz-Venturelli.;Diana Day.;Xiaoqiu Liu.;Qiang Li.;Lili Song.;Thompson G Robinson.;Francisca González.;Francisca Urrutia-Goldsack.;Michael Iacobelli.;Michelle Montalbano.;April Pruski.;Candice Delcourt.;Alice C Durham.;Ahtasam Ebraimo.;Ha Hong Van Ta.;Pratiti Ghosh.;Ann Leonhardt-Caprio.;Huy Thang Nguyen.;Mai Duy Ton.;Stephen Jan.;Hueiming Liu.;Richard I Lindley.;Antonio Arauz.;Andrés Mercado.;Wan Asyraf Wan Zaidi.;Pooja Khatri.;Xia Wang.;Victor C Urrutia.; .
来源: Lancet. 2025年405卷10493期1909-1922页
The universally accepted best practice protocol for monitoring patients who receive intravenous thrombolysis for acute ischaemic stroke was established in the 1990s. However, the protocol is burdensome for nurses, disrupts the sleep of patients, and is potentially less relevant in patients at low risk of symptomatic intracerebral haemorrhage. We aimed to assess whether implementing a low-intensity monitoring protocol would be as safe and effective as standard high-intensity monitoring for patients with acute ischaemic stroke at low risk.
共有 16281 条符合本次的查询结果, 用时 4.1535338 秒